Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538025 | 0.89 | CES1 (0.52) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL7135889 | 0.86 | MMP2 (0.51) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL7405858 | 0.83 | KEAP1 (0.53) | CES1L3MBTL1TDP1HDAC8HDAC6 | |
| SCHEMBL28194343 | 0.82 | L3MBTL1 (0.55) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL8619264 | 0.81 | CES1 (0.64) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL26287745 | 0.81 | TDP1 (0.54) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL1033376 | 0.80 | CES1 (0.59) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL2739376 | 0.78 | TDP1 (0.51) | CES1L3MBTL1TDP1CES2AKR1B1 | |
| SCHEMBL3168036 | 0.76 | CTBP2 (0.51) | MEN1KMT2AHDAC6VNN1ALDH1A1 | |
| SCHEMBL77563 | 0.76 | CES1 (0.70) | CES1L3MBTL1TDP1CES2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966146-B1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| EP-1966146-B1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| EP-1966146-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | CNR1, CNR2, GPR55 | CES1 1156/4885L3MBTL1 4854/4885TDP1 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.